FORX-428 / FoRx Therap - LARVOL DELTA

A phase 1 study of PARG inhibitor FORX-428 in patients with advanced solid tumors harboring DDR alterations or high replication stress (ESMO 2026) - No abstract available

Clinical • Metastases • P1 data • Oncology • Solid Tumor

FORX-428: Exploiting PARG inhibition to target replication stress in cancer cells (AACR 2026) - "We will present the structure of FORX-428, in-depth pharmacology data as well as up-to-date results from the ongoing Phase 1 study. Collectively, these findings provide evidence supporting PARG inhibition as a novel and promising therapeutic strategy to treat PARP inhibitor-resistant and other hard-to-treat cancers."

Oncology • Ovarian Cancer • Solid Tumor

FoRx-06-428 is a novel PARG inhibitor with potent anti-tumor efficacy in preclinical cancer models (AACR 2024) - "Sensitivity to PARG inhibition is partly driven by distinct genomic instabilities, such as defects in homologous recombination (HR) repair, however the activity of PARG inhibitors is also influenced by aberrations in other cancer-relevant pathways. This report represents the first disclosure of the pharmacological characterization of FoRx-06-428 and highlights the value of PARG inhibition as a novel targeted approach to treat DNA repair-deficient cancers."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PARP1

FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition (GlobeNewswire) - "Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitors. Presentation also includes molecular structure and discovery data. Initial data from an open-label Phase 1 study of FORX-428 in patients with advanced solid tumors expected mid-2026."

P1 data • Preclinical • Solid Tumor

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: FoRx Therapeutics AG

New P1 trial • Breast Cancer • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2

FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor (The Manila Times) - "unding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428; Initial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumors"

Financing • P1 data • Solid Tumor

FORX-428: Abest-in class PARG inhibitor with promising anti-tumor activity in preclinical cancer models (AACR-NCI-EORTC 2025) - "Here, we present the in-depth pharmacological characterization of FORX-428 which has recently received IND clearance and entered clinical development. PARG inhibition represents a novel and highly promising strategy for the treatment of cancers harboring specific vulnerabilities in the DNA damage response."

Preclinical • Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response (GlobeNewswire) - "An initial data readout from the trial is expected by mid-2026....FORX-428 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) on June 13, the first patient first visit (FPFV) was on July 22 and the first patient was dosed on August 6."

P1 data • Trial status • Solid Tumor

FoRx Therapeutics...announced the dosing of the first patient in a first-in-human clinical study of FORX-428 (The Manila Times) - "An initial data readout from the trial is expected by mid-2026. The open-label study, initially taking place in the United States, is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard-of-care options...FORX-428 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) on June 13, the first patient first visit (FPFV) was on July 22 and the first patient was dosed on August 6."

P1 data • Trial status • Solid Tumor

FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate (Businesswire) - "...the Company provided an update on its lead development candidate, FORX-428. The compound is an inhibitor of PARG (Poly(ADP-ribose) glycohydrolase) and is being developed for the treatment of solid tumors. FoRx Therapeutics reports significant progress towards IND (Investigational New Drug) submission for FORX-428 and anticipates clearance from the FDA by mid-2025."

IND • Solid Tumor